Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies Shigdar, Sarah, Ward, Alister C., De, Abhijit, Yang, Chaoyong J., Wei, Mingqian and Duan, Wei 2011, Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies, British journal of haematology, vol. 155, no. 1, pp. 3-13, doi: 10.1111/j.1365-2141.2011.08807.x. Attached Files Name Description MIMEType Size Downloads Title Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies Author(s) Shigdar, Sarah Ward, Alister C. orcid.org/0000-0001-7945-7975 De, Abhijit Yang, Chaoyong J. Wei, Mingqian Duan, Wei orcid.org/0000-0001-5782-9184 Journal name British journal of haematology Volume number 155 Issue number 1 Start page 3 End page 13 Total pages 11 Publisher Wiley - Blackwell Publishing Place of publication Oxford, U. K. Publication date 2011-10 ISSN 0007-1048 1365-2141 Keyword(s) aptamers nucleic acid-based therapeutics oligonucleotides RNAi targeted therapeutics Summary Haematological malignancies result from a heterogeneous mix of genetic mutations and chromosome aberrations and translocations. Targeted therapies, such as the anti-CD20 antibody rituximab, or the BCR-ABL1 inhibitor imatinib, have proven to be effective treatments in the management of some of these malignancies, though relapsing or refractory disease is still common. Nucleic acid-based therapies have also entered the clinical arena, providing an alternative, complementary approach. The forerunner of these therapies were the antisense oligonucleotides, but their scope has expanded to include short-interfering RNA (siRNA), microRNA, decoy oligonucleotides and aptamers. These can be used either as monotherapeutics, in conjunction with current chemotherapy regimens, or in combination with each other to improve therapeutic efficacy. Not only can these nucleic acid-based therapies silence target genes, they also have the potential of restoring gene function. While challenges remain in delivering effective doses of nucleic acid in vivo, these are steadily being met, suggesting an optimistic future in the treatment of haematological malignancies. This review summarizes the application of nucleic acid-based therapeutics, particularly aptamers, in the diagnosis and treatment of haematological malignancies. Notes Article first published online 2nd August 2011 Language eng DOI 10.1111/j.1365-2141.2011.08807.x Field of Research 111204 Cancer Therapy (excl Chemotherapy and Radiation Therapy) Socio Economic Objective 920101 Blood Disorders HERDC Research category C1 Refereed article in a scholarly journal ERA Research output type C Journal article Grant ID NHMRC 479505 Copyright notice ©2011, Blackwell Publishing Ltd. Persistent URL http://hdl.handle.net/10536/DRO/DU:30042589 Document type: Journal Article Collection: School of Medicine Related Links Link Description Connect to published version (restricted access) Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Wed, 22 Feb 2012, 11:09:37 EST Wed, 22 Feb 2012, 15:22:25 EST Wed, 22 Feb 2012, 15:23:32 EST Wed, 17 Oct 2012, 14:11:31 EST Fri, 13 Jun 2014, 12:59:29 EST Mon, 19 Jan 2015, 11:34:50 EST Filtered Full Citation counts:   Cited 17 times in TR Web of Science Cited 17 times in Scopus Search Google Scholar Access Statistics: 346 Abstract Views, 2 File Downloads  -  Detailed Statistics Created: Wed, 22 Feb 2012, 11:09:30 EST by Jane Moschetti

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.